






Engineering synthetic agonists for targeted activation of Notch signaling

Received: 25 September 2024

Accepted: 20 August 2025

Published online: 24 September 2025

 Check for updates

David H. Perez , Daniel Antfolk , Shiun Chang, Xiomar E. Bustos , Elliot Medina , Ahmed A. Ramadan, David Gonzalez-Perez , Daniel Abate-Daga, Paulo C. Rodriguez  & Vincent C. Luca  

Notch signaling regulates cell fate decisions and has context-dependent tumorigenic or tumor suppressor functions. Although there are several classes of Notch inhibitors, the mechanical force requirement for Notch activation has hindered attempts to generate soluble agonists. To address this problem, we engineered synthetic Notch agonists (SNAGs) by tethering affinity-matured Notch ligands to proteins that internalize their targets. This bispecific format enables SNAGs to ‘pull’ on mechanosensitive Notch receptors, triggering their activation in the presence of desired biomarkers. We successfully developed SNAGs targeting six independent surface markers, including the tumor antigens PDL1, CD19 and HER2 and the immunostimulatory receptor CD40. HER2-SNAGs and CD19-SNAGs increased the expression of T cell activation markers and Notch target genes in cocultures with tumor cells, highlighting their potential for immunotherapeutic applications. These insights have broad implications for the pharmacological activation of mechanoreceptors and will expand our ability to modulate Notch signaling in biotechnology.

The Notch pathway is a cell-to-cell communication system that regulates embryonic development, tissue homeostasis and immune cell differentiation. The signaling of mechanosensitive Notch receptors is tightly regulated¹ and aberrant Notch activity causes various human diseases². For example, loss-of-function mutations in Notch components are linked to the development of aortic valve disease (Notch1), Alagille syndrome (Notch2 and Jagged1 (JAG1)), CADASIL (Notch3) and spondylocostal dysostosis (Delta-like ligand 3 (DLL3))^{3–6}. In cancer, Notch functions as a tumor suppressor or oncogene depending on the cell type and both loss-of-function and hyperactivating mutations influence tumorigenesis and disease progression⁷. Notch is also pleiotropic with respect to its guidance of cell fate decisions, in that Notch activation stimulates either proliferation or differentiation in different stem cell populations⁸. These diverse functions suggest that Notch agonists and antagonists may each be viable therapeutics in certain biomedical contexts⁹.

The role of Notch in T cell biology has led to the development of Notch-based strategies for enhancing cancer immunotherapy. Notch signaling is important for several natural stages of T cell maturation¹⁰

and *ex vivo* Notch activation is required for the differentiation of T cells from hematopoietic stem cells¹¹. This latter function may potentially be used to generate allogeneic T cells for ‘off-the-shelf’ adoptive T cell or chimeric antigen receptor T cell therapies. More recently, Notch activation has been shown to enhance the antitumor function of fully mature, activated T cells¹². Genetic overexpression of an activated form of Notch¹³ and culturing T cells in the presence of Notch1-specific antibodies¹⁴ or ligand-expressing cells¹⁵ were each associated with improved tumor clearance in various animal models of cancer. Detailed analysis of the T cells used in these studies revealed that these phenotypes were because of the Notch-stimulated induction of exhaustion-resistant or stem-like phenotypes.

At the molecular level, Notch receptors are massive (~290 kDa) transmembrane proteins that are activated by a distinctive, mechanical force-driven mechanism^{1,16–18}. Notch signaling is initiated when a DLL or JAG ligand forms a *trans*-interaction with a Notch receptor on the surface of an adjacent cell^{1,19–21}. Endocytosis of the ligand then generates a ‘pulling’ force that propagates to the negative regulatory region (NRR) of Notch^{16,22}. This pulling destabilizes the NRR, which exposes internal

cleavage sites for processing by the intramembrane proteases ADAM10 (S2 cleavage) and γ -secretase (S3 cleavage)^{23,24}. Following these proteolytic events, the Notch intracellular domain (NICD) translocates to the nucleus to function as a transcriptional coactivator²⁵.

Although Notch inhibitors are widely available, soluble agonists are challenging to engineer because they must somehow ‘pull’ on the Notch receptor despite lacking a method of force generation^{9,18}. Multiple strategies have been developed to activate Notch receptors in vitro through mimicry of the physiological activation process. Notch signaling may be induced through coculture of Notch-expressing cells and ligand-expressing cells, by culturing Notch-expressing cells on plates coated with ligands or antibodies or through administration of ligand-coated microbeads^{14,26,27}. Thus far, the only Notch agonist antibody, A13, functions by destabilizing the metastable NRR domain of Notch3 (refs. 28–30). Unfortunately, this NRR unfolding approach has been ineffective for receptor subtypes with stable NRRs (for example, Notch1, Notch2 and Notch4). Oligomerized ligands have also shown limited promise as agonists. For example, preclustering DLL1–Fc fusions with anti-Fc antibodies, JAG1-coated DNA origami structures and DLL4 proteins fused to designed trimeric scaffolds (C3–DLL4) stimulate low levels of Notch activation in vitro^{31–33}.

Here we engineered bispecific proteins that stimulate activation of Notch signaling in desired cellular contexts. We successfully developed SNAGs that enhance the signaling of weakly activating JAG1 ligands and those that selectively activate Notch in the presence of the several immunologically relevant cell surface biomarkers. Furthermore, we show that SNAGs stimulate increased expression of Notch target genes and T cell activation markers in primary human T cells. The modularity and versatility of this SNAG platform provide a blueprint for the development of a diverse repertoire of Notch-based biologics.

Results

Soluble DLL4 ligand multimers do not activate Notch signaling

As an initial attempt to generate Notch agonists, we investigated whether soluble oligomers of an affinity-matured DLL4 ligand (Delta^{MAX}) activate Notch signaling³⁴. Delta^{MAX} contains ten mutations that increase its affinity for human Notch receptors by 500-fold to 1,000-fold ($K_D = 24$ to 54 nM), making it a more potent activator than DLL4 ($K_D > 10 \mu\text{M}$) in coculture and plate-bound formats³⁴. We hypothesized that this increased affinity, coupled with receptor crosslinking through multimerization, could introduce tension in the absence of an endocytic pulling force. To test this hypothesis, we incubated Notch1–Gal4 mCitrine reporter cells³⁵ with soluble and immobilized Delta^{MAX} multimers (Fig. 1a–c). Delta^{MAX} dimers were generated through the C-terminal addition of a dimeric human IgG1 Fc domain (Fig. 1b) and tetramers were generated by premixing a 4:1 molar ratio of biotinylated Delta^{MAX} with streptavidin (SA) (Fig. 1c). We found that neither the monomers nor the multimers induced reporter activity. By contrast, the plated Delta^{MAX} ligands potently stimulated Notch1 activation (Fig. 1a–c). This indicates that the receptor crosslinking by Delta^{MAX}–Fc dimers and Delta^{MAX}–SA tetramers is insufficient for signaling activation.

Design of synthetic Notch agonists

To develop soluble Notch agonists, we engineered bispecific proteins that recapitulate the endocytosis-linked activation mechanism of DLL and JAG ligands (Fig. 1d). SNAGs were created by fusing Delta^{MAX} to the N terminus of biomarker-targeting antibody fragments through a flexible (GS)₃ linker or by fusing Delta^{MAX} and antibody fragments to the N- and C- termini of a dimeric IgG1 Fc domain (Fig. 1e). These design concepts are intended to form a ‘molecular bridge’ between Notch-expressing cells and cells that express a given surface protein. Conceptually, SNAGs should then activate Notch if the enforced interactions induce endocytic or tensile force capable of unfolding the NRR. To this end, a modular SNAG platform (Fig. 1f) was developed to have exchangeable modules for biomarker-specific SNAGs against canonical

Notch ligands (Fig. 1g), biomarkers upregulated in tumors (Fig. 1h) and an immunostimulatory biomarker (Fig. 1i).

SNAGs rescue the signaling of a signaling-deficient DLL4 mutant

To demonstrate proof of concept, we tested whether SNAGs could rescue the activity of a signaling-deficient DLL4 mutant. Loss-of-function DLL4 cells were generated by expressing a ‘headless’ DLL4 truncation where the Notch-binding C2 and DSL domains^{20,36} were replaced with a BC2 epitope tag (BC2–DLL4^{HL}) (Fig. 2a and Supplementary Fig. 1a)³⁷. BC2–SNAGs were then generated by fusing Delta^{MAX} to a BC2-specific nanobody (Fig. 2a,b and Supplementary Fig. 2a). We found that BC2–DLL4^{HL} cells alone did not activate signaling in a Notch1–Gal4 mCitrine reporter assay, whereas the addition of 1–100 nM SNAGs stimulated a dose-dependent increase in reporter activity (Fig. 2c and Supplementary Fig. 3a–c). Monomeric BC2–SNAGs containing the (GS)₃ linker (BC2–SNAG) stimulated a ~6-fold increase in Notch1 signaling, whereas dimeric BC2–SNAG–Fc fusion proteins (BC2–SNAG^{Fc}) were more effective and induced a ~10-fold increase (Fig. 2c). Importantly, administration of the monomeric or dimeric BC2–SNAGs alone did not substantially increase Notch1 reporter activity, indicating that a mixture of target-expressing and nonexpressing cells is required for SNAG-mediated activation (Fig. 2c).

SNAGs bolster the activity of weakly signaling JAG1 ligands

DLL or JAG ligands preferentially signal through certain Notch receptor subtypes and JAG1 is a particularly weak activator of Notch1 (ref. 38). Therefore, we tested whether a JAG1-targeting SNAG (JAG1–SNAG^{Fc}) could potentiate JAG1–Notch1 signaling. In the JAG1–SNAG^{Fc} construct, Delta^{MAX} and a single-chain variable fragment (scFv) derived from the JAG1-targeting antibody B70 (ref. 39) were fused to the N and C termini of an IgG1 Fc domain as described above (Supplementary Fig. 2b). We then performed a signaling assay to measure the activation of Notch1 reporter cells by JAG1-overexpressing HEK293 cells (JAG1-293 cells) in the presence or absence of the SNAG. We found that addition of the JAG1–SNAG^{Fc} increased Notch1 reporter activity ~4-fold compared to JAG1-293 cells alone and JAG1-293 cells did not stimulate a significant increase in reporter activity (Fig. 2d and Supplementary Fig. 1b). We also evaluated the JAG1–SNAG^{Fc} with a JAG1–H268Q ‘nodder’ mutant that causes Alagille syndrome-like symptoms in mice by decreasing JAG1–Notch1 binding (Supplementary Fig. 1c). Addition of the JAG1–SNAG^{Fc} to cocultures of Notch1 and JAG1–H268Q cells increased JAG1 signaling up to sevenfold compared to Notch1 cells alone (Fig. 2e). These data indicate that SNAGs can function as ‘signaling enhancers’ by potentiating the activity of endogenous or mutated ligands.

SNAGs targeting tumor antigens activate Notch in mixed cell populations

We next tested whether SNAGs targeting the tumor antigens PDL1, CD19 or HER2 (Fig. 1h) can stimulate Notch activation. There is mounting evidence that Notch signaling enhances the function of activated T cells^{13–15} and SNAGs localized to the tumor microenvironment have the potential to stimulate localized activation of tumor-associated lymphocytes. For these SNAGs, the targeting arms were derived from antibody–drug conjugates (ADCs) that were preselected for their ability to induce target internalization. We hypothesized that SNAGs incorporating ADC antibodies could, thus, mimic the physiological endocytosis mechanism of DLL or JAG ligands.

We generated monomeric and dimeric PDL1–SNAGs by fusing Delta^{MAX} to an scFv derived from the ADC antibody atezolizumab^{40,41}. In the monomeric PDL1–SNAG, Delta^{MAX} and the scFv were connected using a (GS)₃ linker, whereas, in the dimeric PDL1–SNAG (PDL1–SNAG^{Fc}), Delta^{MAX} and the scFv were fused to the N and C termini of an IgG1 Fc domain (Fig. 1h and Supplementary Fig. 2a). Unexpectedly, addition of the monomeric PDL1–SNAG to a 1:1 mixture of Notch1 reporter cells and PDL1-expressing MDA-MB-231 cells did not activate Notch1 (Fig. 3a and




Fig. 1 | Design concept for synthetic Notch agonists. a, Flow cytometry histogram overlay of Notch1 reporter cells stimulated by soluble or plated (nonspecifically adsorbed) Delta^{MAX}. The cartoon depicts the site-specifically biotinylated Delta^{MAX} (N-EGF5) construct. **b**, Histogram overlay of Notch1 reporter cells stimulated with soluble or plated Delta^{MAX}-Fc protein. **c**, Histogram overlay of Notch1 reporter cells stimulated with plated or soluble Delta^{MAX}-SA tetramers. **d**, Cartoon schematic depicting the ECDs of Notch1 and DLL4

interacting during canonical Notch activation. The NRR and ligand-binding domains (LBDs) of Notch1 (EGF domains 8–12) are shaded. **e**, Schematic of a generalized SNAG construct alongside a cartoon depicting SNAG-mediated Notch activation. **f**, Representation of the modular design of SNAGs. **g–i**, Top: schematic highlighting targets of SNAGs separated by canonical Notch ligands (**g**), tumor biomarkers (**h**) and B cell biomarker (**i**). Bottom: the corresponding endocytic mechanism.

Supplementary Fig. 1d). On the other hand, the dimeric PDL1-SNAG^{Fc} protein stimulated a ~7-fold increase in Notch1 signaling in the coculture, suggesting that multimerization or avidity enhancement may be required for SNAGs to effectively target biomarkers other than Notch ligands (Fig. 3a). Neither PDL1-SNAG nor PDL1-SNAG^{Fc} substantially increased Notch1 reporter activity in the absence of MDA-MB-231 cells. To test the importance of Notch-binding affinity in SNAG design, we generated a PDL1-SNAG^{Fc} incorporating wild-type DLL4 (Supplementary Fig. 2d), which binds to Notch1 with ~1,000-fold decreased affinity

($K_D = 24.7 \mu\text{M}$) compared to Delta^{MAX} ($K_D = 24 \text{ nM}$). We found that the wild-type DLL4 SNAG was unable to activate Notch1 at all concentrations tested (Supplementary Fig. 4), indicating that the enhanced binding of the Delta^{MAX} variant is essential for SNAG function.

SNAGs do not activate signaling on cells expressing both Notch1 and PDL1

Given the ubiquitous expression of Notch1 in mammalian cells, it is conceivable that SNAGs could activate signaling when Notch1 and




Fig. 2 | SNAGs rescue the signaling of binding-deficient DLL4 and JAG1 mutants. **a**, Cartoon schematic depicting a SNAG binding to Notch1 and a loss-of-function DLL4 mutant. DLL4^{HL} was generated by replacing the Notch-binding C2-DSL region with a BC2 peptide epitope recognized by the anti-BC2 nanobody. **b**, Cartoon schematic depicting the multivalent binding of BC2-SNAG^{Fc} to Notch1 and DLL4^{HL}. **c–e**, Fluorescent reporter assays were used to evaluate SNAG-mediated activation of Notch1 in cocultures with HEK293T cells expressing DLL4^{HL} (**c**), JAG1 (**d**) or JAG1-H268Q (**e**). Increasing concentrations

(1 nM, 10 nM or 100 nM) of the indicated SNAGs were added to Notch1–Gal4 Citrine reporter cells alone or to a 1:1 mixture of Notch1 reporter cells and HEK293 cells expressing DLL4^{HL}; fluorescence was measured by flow cytometry. A representative experiment from three biological replicates is shown. The MFI was normalized to the MFI of Notch1 reporter cells alone. Error bars represent the s.d. of $n = 3$ technical replicates, with the P value determined using a two-sided Student's t -test shown above each comparison.

the target protein are both present on the cell surface. To test this possibility, we cultured MDA-MB-231 cells in the presence of soluble Delta^{MAX}-Fc, PDL1-SNAG^{Fc} or immobilized Delta^{MAX}-Fc and monitored the levels activated Notch1 by western blot (Fig. 3b). We found that the plated Delta^{MAX}-Fc protein stimulated high levels of Notch1 activation, whereas PDL1-SNAG^{Fc} did not induce signaling over the background levels observed for soluble Delta^{MAX}-Fc alone (Fig. 3b). The inability of SNAGs to activate Notch1 in MDA-MB-231 cells suggests that the present design does not enable sufficient intercellular crosslinking in cultures of cells expressing both Notch1 and the biomarker.

Development of SNAGs targeting CD19, HER2 and CD40

To generate a SNAG targeting the B lymphocyte antigen CD19, we used an scFv derived from the CD19-targeting ADC loncastuximab⁴² to the C terminus of Delta^{MAX}-Fc (CD19-SNAG^{Fc}) (Supplementary Fig. 2a).

CD19-SNAG was then added to Notch1 reporter cells or to cocultures of Notch1 reporter cells and CD19-overexpressing 3T3 fibroblast cells (Supplementary Fig. 1e). We found that the CD19-SNAG^{Fc} protein stimulated up to a sixfold increase in reporter activity in the coculture compared to untreated Notch1 cells (Fig. 3c). To generate a SNAG targeting the breast cancer antigen HER2 (HER2-SNAG^{Fc}), we replaced the CD19-targeting arm with an scFv derived from the HER2-targeting ADC trastuzumab⁴³ (Supplementary Fig. 2c). Addition of HER2-SNAG^{Fc} to a mixed culture of Notch1 reporter cells and HER2-expressing SK-BR-3 breast cancer cells induced a sixfold increase in reporter activity (Fig. 3d and Supplementary Fig. 1f) at the highest concentration tested (100 nM), which is similar to the level of activation we observed for the PDL1-SNAG^{Fc} and the CD19-SNAG^{Fc} constructs (Fig. 3a,c). In the absence of biomarker-expressing cells, neither CD19-SNAG^{Fc} nor HER2-SNAG^{Fc} stimulated a significant increase in

signaling compared to Delta^{MAX}-Fc alone (Fig. 3c,d). Our collective development of PDL1-SNAGs, CD19-SNAGs and HER2-SNAGs demonstrates that SNAGs can facilitate signaling by engaging cell surface proteins beyond endogenous ligands.

We also generated a SNAG targeting CD40 (CD40-SNAG), an immunostimulatory receptor that undergoes endocytosis upon binding to CD40 ligand (CD40L)^{44,45}. We hypothesized that a CD40-SNAG could be used to activate Notch in CD40⁻ T cells in the presence of CD40⁺ B cells, as these cell types are known to colocalize in germinal centers, the tumor microenvironment and peripheral blood⁴⁶. To generate a CD40-SNAG, we fused Delta^{MAX} and the extracellular domain (ECD) of CD40L to the N and C termini of a trimeric leucine zipper⁴⁷ (Fig. 1i and Supplementary Fig. 2e), respectively. This trimeric scaffold was selected instead of an Fc domain for CD40-SNAG because CD40L is naturally a homotrimer. We found that the addition of CD40-SNAG robustly activated Notch in mixed cultures of Notch1 reporter cells and CD40-expressing OCI-Ly3 cells (Supplementary Fig. 1g) but only weakly in Notch1 reporter cells alone (Fig. 3e). The OCI-Ly3 cells used in this assay are nonadherent, indicating that SNAGs also facilitate Notch activation between adherent and suspension cells.

Comparison of SNAGs to conventional methods of Notch activation

To assess the relative effectiveness of SNAGs, we compared Notch activation levels of the soluble PDL1-SNAG^{Fc} and various conventional methods of Notch agonism. In this assay, Notch reporter cells were stimulated with plated Delta^{MAX}-Fc, plated DLL4-Fc, EDTA, DLL4-expressing HEK293T cells and PDL1-SNAG^{Fc} in the presence of PDL1-expressing cells (Fig. 3f). In the plate-bound format, 100 nM concentrations of each ligand were nonspecifically adsorbed to the surfaces and 100 nM concentrations of SNAG were added to the coculture. We found that, in the presence of PDL1-expressing cells, PDL1-SNAG^{Fc} induced higher levels of reporter activity than all methods of activation except for the plated Delta^{MAX}-Fc protein, which has been shown to exhibit superagonist activity³⁴. Notably, PDL1-SNAG^{Fc} stimulated higher levels of signaling than DLL4-overexpressing cells, which typically serve as a benchmark for Notch activation. The DLL4-Fc protein did not detectably activate Notch1 in this format, which may be because of the lack of C-terminally anchored coupling required for optimal signaling with wild-type ligands^{34,48}.

Endocytosis is required for SNAG-mediated Notch activation

Ligand endocytosis is important for Notch activation⁴⁹ and this process is regulated by ubiquitination of DLL or JAG ICDs by the E3 ligase Mind bomb1 (refs. 50–52). To determine whether endocytosis occurs with a SNAG targeting a surface protein other than a natural Notch ligand, we performed an immunofluorescence endocytosis assay using CD19-SNAG^{Fc} in CD19-expressing cells. CD19-SNAG^{Fc} coupled with a fluorescent secondary antibody (Alexa Fluor 647-labeled anti-Fc) bound strongly to the surface of the CD19-expressing cells when the mixture

was incubated on ice (Fig. 4a and Supplementary Fig. 5a–c). Following CD19-SNAG^{Fc} binding, incubation at 37 °C permitted the resumption of cellular activity, including endocytosis. Visualizing the cells after a 15-min incubation at 37 °C showed that the majority of bound CD19-SNAG^{Fc} was internalized (Fig. 4b and Supplementary Fig. 5e–d). Performing the assay in the presence of the dynamin-dependent endocytosis inhibitor Dynasore blocked SNAG uptake, further supporting our observation that SNAGs are internalized (Fig. 4c).

To test whether endocytosis is necessary for SNAG signaling, we coadministered SNAGs with Dynasore. We found that Dynasore completely ablated the activity of CD19-SNAG^{Fc} in cocultures of Notch1-expressing and CD19-expressing cells, indicating that endocytosis is required for SNAG-mediated activation using CD19 as a biomarker (Fig. 4d). We further found that BC2-SNAGs targeting BC2-DLL4^{HL} were unable to activate Notch1 in cocultures of Notch1 and BC2-DLL4^{HL} cells in the presence of Dynasore, confirming that endocytosis is also required for SNAG-mediated rescue of DLL4 signaling (Fig. 4e,f). Interestingly, we found that immobilized SNAGs were also unable to activate Notch1 in the presence of Dynasore, suggesting that endocytosis in the Notch receptor cell is essential for Notch activation by plated ligands (Fig. 4g). These studies demonstrate that Notch activation by plated ligands, SNAGs targeting a DLL4 loss-of-function mutant and SNAGs targeting tumor antigens each depend on endocytosis.

SNAGs stimulate the expression of T cell activation markers

To investigate whether bispecific SNAGs influence the behavior of activated T cells, we established in vitro cocultures of primary human CD8⁺ T cells with tumor cells expressing the SNAG targets PDL1 or HER2 (Fig. 5a). The cocultures were then treated with PDL1-SNAG^{Fc} or HER2-SNAG^{Fc} and then activated with anti-CD28-coated or anti-CD3-coated beads. We found that the addition of PDL1-SNAG^{Fc} or HER2-SNAG^{Fc} but not Delta^{MAX}-Fc increased the proportion of granzyme B (GrB)-expressing CD8⁺ T cells, which is indicative of a cytotoxic phenotype. At the transcriptional level, SNAG-treated T cells showed elevated expression of *GZMB* and *IFNG*, key markers of effector function, and *HES4*, a canonical Notch target gene (Fig. 5b,c). In the PDL1-SNAG^{Fc}-treated cocultures, *GZMB*, *IFNG* and *HES4* were upregulated 18-fold, 37-fold and 3-fold, respectively, relative to untreated controls. Similarly, treatment with HER2-SNAG^{Fc} resulted in 4-fold, 52-fold and 16-fold increases in *GZMB*, *IFNG* and *HES4* expression, respectively. This increased expression could be additionally found at the protein level, as intracellular staining followed by flow cytometry revealed increased GrB and interferon- γ (IFN γ) expression in SNAG-treated T cells (Supplementary Fig. 6a,b).

Discussion

The development of soluble agonists has been an enduring challenge in the Notch field^{9,53}. The SNAG platform described here offers a solution to this problem and provides a framework for the development of

Fig. 3 | SNAGs targeting tumor antigens activate Notch in mixed cell populations.


a, Increasing concentrations (1 nM, 10 nM or 100 nM) of Delta^{MAX}-Fc, PDL1-SNAG or PDL1-SNAG^{Fc} were added to Notch1-Gal4 mCitrine reporter cells alone or in a 1:1 coculture with PDL1-expressing MDA-MB-231 cells and fluorescence was measured by flow cytometry. **b**, MDA-MB-231 cells were incubated with PDL1-SNAG^{Fc}, soluble Delta^{MAX}-Fc or plated Delta^{MAX}-Fc and Notch1 activation was assessed by Western Blot using an antibody to the cleaved NICD. Data represent a single experiment ($n = 1$). **c**, Increasing concentrations (1 nM, 10 nM or 100 nM) of Delta^{MAX}-Fc or CD19-SNAG^{Fc} were added to Notch1 reporter cells or 1:1 mixtures of reporter cells and CD19-expressing 3T3 cells. **d**, Increasing concentrations (1 nM, 10 nM or 100 nM) of Delta^{MAX}-Fc or HER2-SNAG^{Fc} were added to Notch1 reporter cells or 1:1 mixtures of reporter cells and HER2-expressing SK-BR-3 cells. **e**, Increasing concentrations (1 nM, 10 nM or 100 nM) of trimeric CD40-SNAG or Delta^{MAX}-Fc were added to

reporter cells alone or 1:2 mixtures of Notch1 reporter cells and CD40-expressing OCI-Ly3 cells. **f**, Notch1 reporter cells were stimulated with plated Delta^{MAX}-Fc, DLL4-Fc, EDTA, DLL4-expressing HEK293T cells and PDL1-SNAG^{Fc} in the presence of MDA-MB-231 cells and fluorescence was measured using flow cytometry. The dashed line denotes the activation level induced by cellular activation with HEK293T-DLL4 cells. Ligands were adsorbed at 100 nM concentrations, EDTA was added to a concentration of 1 mM and soluble PDL1-SNAG^{Fc} was added to a concentration of 100 nM. For **a**, **c**–**f**, a representative experiment from three biological replicates is shown. The MFI was normalized to the MFI of Notch1 reporter cells alone. Error bars represent the s.d. of $n = 3$ technical replicates, with the P value determined using a two-sided Student's t -test shown above each comparison ($P = 6.467 \times 10^{-7}$ in comparison of Delta^{MAX}-Fc to CD40-SNAG at 10 nM).

a diverse array of Notch activating biologics. Such agents have a wide range of potential translational applications, particularly in cancer where Notch functions as a tumor suppressor⁷, T cell manufacturing^{11,27}, T cell immunotherapy^{13–15}, wound healing⁵⁴ and other areas of regenerative medicine. These first-generation SNAGs were engineered using an

Fc fusion format used in clinically viable protein drugs, which may also help to accelerate in vivo translation.

In their present form, SNAGs facilitate potent activation of Notch signaling in mixed populations of cells. It is possible that these designs may be further affinity-tuned to improve SNAG function. For example,







Fig. 4 | SNAG-mediated Notch activation requires endocytosis.

a, Representative immunofluorescence images of fluorescently labeled CD19-SNAGs (magenta) used to stain the surface of CD19-expressing 3T3 cells that were kept on ice. CD19-SNAGs visualized by Alexa Fluor anti-Fc 647. To visualize the contours of the cells, the actin cytoskeleton was stained using phalloidin 488 (green). Nuclei were counterstained by Hoechst 33342 (blue). Scale, 20 μ m. **b,c**, Representative immunofluorescence images of fluorescently labeled CD19-SNAGs used to stain the surface of CD19-expressing 3T3 cells in the absence (**b**) or presence (**c**) of Dynasore, followed by washing away unbound SNAGs and subjecting the cells to a 15-min incubation in a 37 °C incubator to resume cellular processes, including endocytosis. After 15 min, the cells were fixed and stained in parallel with the no endocytosis samples. Scale, 20 μ m.



A representative staining is shown for each experimental condition from one of two biological replicates. **d–g**, Flow cytometry histogram overlays depicting Notch1 reporter activity induced by soluble CD19-SNAG^{Fc}, BC2-SNAG or BC2-SNAG^{Fc} in the presence or absence of Dynasore. **d**, Notch1 reporter cells were cocultured with CD19-overexpressing 3T3 cells. In **e,f**, Notch1 reporter cells were cocultured with HEK293 cells expressing DLL4^{HL}. **g**, Flow cytometry histogram overlay depicting Notch1 reporter activity induced by immobilized BC2-SNAG in the presence or absence of Dynasore. A representative histogram is shown for each experimental condition from one biological replicate for CD19-SNAG^{Fc} (soluble), two biological replicates for BC2-SNAG (soluble) or three biological replicates for both BC2-SNAG^{Fc} (soluble) and BC2-SNAG (plated).

the Delta^{MAX} arm ($K_D = 24$ nM) and the JAG1-targeting, PDL1-targeting and HER2-targeting arms ($K_D = 0.9$ nM, 1.8 nM and 5 nM, respectively) bind with similar affinities^{34,39,55,56}. Lowering the affinity of the Notch-binding arm may, therefore, improve specificity and tissue distribution, as observed for bispecific inhibitory antibodies⁵⁷ and T cell engagers⁵⁸. On the other hand, we also demonstrated that wild-type DLL4 was ineffective when incorporated into SNAGs, suggesting that there is a lower limit for the allowable affinity range. Additionally, higher-order oligomers beyond the dimeric and trimeric SNAG scaffolds tested here may lead to increased signaling potency. Future studies will focus on optimizing affinity and multimerization to maximize signaling while maintaining favorable biochemical properties.

One surprising observation was that PDL1-SNAGs did not activate signaling on cells expressing both PDL1 and Notch1. We speculate that these SNAGs engage the two targets in *cis* on the surface of a single cell, as opposed to bridging PDL1 and Notch1 proteins between cells; moreover, *cis* interactions do not introduce sufficient tension to unfold the NRR. This may be attributed to the restricted diffusion of SNAGs in the two-dimensional environment of the membrane, which can promote preferential *cis* interactions by increasing the local concentration. Previous studies showed that *cis* inhibition of Notch signaling occurs when ligands and receptors are expressed on the same cell^{35,59} and it appears that SNAGs are similarly unable to activate Notch in this context. Regardless, the ability of SNAGs to mediate unidirectional signaling enables highly selective targeting, which could minimize the risks of potential toxicity from global Notch agonism.

There has been longstanding interest in using Notch to manufacture off-the-shelf CD4⁺ or CD8⁺ T cells for immunotherapy⁶⁰. By contrast, the use of Notch agonists to bolster the effector function of mature or activated T cells emerged more recently and the advantages of this strategy have not been thoroughly vetted⁶¹. Here, we showed that the addition of PDL1-SNAGs or HER2-SNAGs can stimulate Notch signaling in CD8⁺ T cells cocultured with tumor cells expressing the target biomarkers. T cells stimulated in this fashion also had increased expression of the T cell activation markers GrB and IFN γ . These findings suggest that injected SNAGs may have the potential enhance the function of adoptively transferred T cells *in vivo* similarly to what has been achieved *ex vivo* with immobilized agonists; however, these predictions will require validation in animal models.

An important consideration in SNAG design, especially in the context of immunotherapy, is the ubiquitous expression of Notch receptors in nearly all cell types. In addition to effector T cells, regulatory T cells, myeloid-derived suppressor cells, macrophages and other immune cells are all typically present in the tumor microenvironment. Activation of Notch may not be desirable in all of these populations and has the potential to induce a range of immunostimulatory and immunosuppressive phenotypes. The ubiquitous expression of Notch proteins may also hinder the tissue distribution of SNAGs or result in Notch inhibition in the absence of a relevant biomarker. Further modifications may, thus, be necessary to maximize on-target Notch activation with SNAGs or alternative agonists scaffolds.




Fig. 5 | SNAGs increase activation markers of CD8⁺ T cells. PBMCs were used to isolate naïve CD8⁺ T cells that were treated with 100 nM Delta^{MAX}-Fc, PDL1-SNAG^{Fc} or HER2-SNAG^{Fc} or not treated (control) in the presence of PDL1⁺ MDA-MB-231 cells or HER2⁺ SK-BR-3 cells, followed by human CD3 and CD28 stimulation for 48 h before isolation. **a**, Schematic depicting a SNAG engaging the target biomarkers expressed on a tumor cell and Notch receptors of a CD8⁺

T cell. **b,c**, The first bar chart shows the percentage of CD8⁺ and GrB⁺ T cells and subsequent three bar charts show the relative mRNA levels for *GZMB*, *IFNG* and *HES4* normalized to the control; each bar represents the fold change. Error bars represent the s.d. of $n = 3$ technical replicates, with the P value determined using a two-sided Student's t -test shown above each comparison.

While SNAGs are effective in mixed cell populations, the development of ‘unconditional’ agonists (that is, those that do not rely on a secondary target) remains a challenging problem. The NRR of Notch3 appears to be uniquely susceptible to antibody-mediated destabilization^{29,30}, whereas the engineering of agonists targeting other Notch receptors with more stable NRRs may require alternative solutions. In vitro activation of Notch1 with ligands fused to DNA origami structures, Fc-clustered DLL1 proteins and trimerization scaffolds suggests that induced receptor clustering may be an effective strategy^{31–33}. The recent development of the trimeric C3-DLL4 agonists is the most promising among these approaches, as it is capable of stimulating Notch in T cell bioreactors and ameloblasts derived from induced pluripotent stem cells^{33,62}. However, in vitro use of this method requires multiple rounds of doxycycline induction of Notch expression over a prolonged 96-h incubation period to activate Notch. Despite these limitations, the development of SNAGs and the related technologies above represent a key first step toward the widespread implementation of Notch agonists for basic and translational research.

Online content

Any methods, additional references, Nature Portfolio reporting summaries, source data, extended data, supplementary information, acknowledgements, peer review information; details of author contributions and competing interests; and statements of data and code availability are available at <https://doi.org/10.1038/s41589-025-02030-y>.

References

1. Sprinzak, D. & Blacklow, S. C. Biophysics of Notch signaling. *Annu. Rev. Biophys.* **50**, 157–189 (2021).
2. Zhou, B. et al. Notch signaling pathway: architecture, disease, and therapeutics. *Signal. Transduct. Target. Ther.* **7**, 1–33 (2022).
3. Garg, V. et al. Mutations in *NOTCH1* cause aortic valve disease. *Nature* **437**, 270–274 (2005).
4. Li, L. et al. Alagille syndrome is caused by mutations in human *Jagged1*, which encodes a ligand for Notch1. *Nat. Genet.* **16**, 243–251 (1997).
5. Joutel, A. et al. *Notch3* mutations in CADASIL, a hereditary adult-onset condition causing stroke and dementia. *Nature* **383**, 707–710 (1996).
6. Bulman, M. P. et al. Mutations in the human Delta homologue, *DLL3*, cause axial skeletal defects in spondylocostal dysostosis. *Nat. Genet.* **24**, 438–441 (2000).
7. Radtke, F. & Raj, K. The role of Notch in tumorigenesis: oncogene or tumour suppressor? *Nat. Rev. Cancer* **3**, 756–767 (2003).
8. Hori, K., Sen, A. & Artavanis-Tsakonas, S. Notch signaling at a glance. *J. Cell Sci.* **126**, 2135–2140 (2013).
9. Andersson, E. R. & Lendahl, U. Therapeutic modulation of Notch signalling—are we there yet? *Nat. Rev. Drug Discov.* **13**, 357–378 (2014).
10. Brandstadter, J. D. & Maillard, I. Notch signalling in T cell homeostasis and differentiation. *Open Biol.* **9**, 190187 (2019).
11. Schmitt, T. M. & Zúñiga-Pflücker, J. C. Induction of T cell development from hematopoietic progenitor cells by Delta-like-1 in vitro. *Immunity* **17**, 749–756 (2002).
12. Kelliher, M. A. & Roderick, J. E. NOTCH signaling in T-cell-mediated anti-tumor immunity and T-cell-based immunotherapies. *Front. Immunol.* **9**, 1718 (2018).

13. Sierra, R. A. et al. Rescue of Notch-1 signaling in antigen-specific CD8⁺ T cells overcomes tumor-induced T-cell suppression and enhances immunotherapy in cancer. *Cancer Immunol. Res* **2**, 800–811 (2014).
14. Wilkens, A. B. et al. Notch1 signaling during CD4⁺ T-cell activation alters transcription factor networks and enhances antigen responsiveness. *Blood* **140**, 2261–2275 (2022).
15. Kondo, T. et al. Notch-mediated conversion of activated T cells into stem cell memory-like T cells for adoptive immunotherapy. *Nat. Commun.* **8**, 15338 (2017).
16. Meloty-Kapella, L., Shergill, B., Kuon, J., Botvinick, E. & Weinmaster, G. Notch ligand endocytosis generates mechanical pulling force dependent on dynamin, epsins, and actin. *Dev. Cell* **22**, 1299–1312 (2012).
17. Wang, X. & Ha, T. Defining single molecular forces required to activate Integrin and Notch signaling. *Science* **340**, 991–994 (2013).
18. Gordon, W. R. et al. Mechanical allostery: evidence for a force requirement in the proteolytic activation of Notch. *Dev. Cell* **33**, 729–736 (2015).
19. Rebay, I. et al. Specific EGF repeats of Notch mediate interactions with Delta and Serrate: implications for Notch as a multifunctional receptor. *Cell* **67**, 687–699 (1991).
20. Luca, V. C. et al. Structural basis for Notch1 engagement of Delta-like 4. *Science* **347**, 847–853 (2015).
21. Luca, V. C. et al. Notch–Jagged complex structure implicates a catch bond in tuning ligand sensitivity. *Science* **355**, 1320–1324 (2017).
22. Gordon, W. R. et al. Structural basis for autoinhibition of Notch. *Nat. Struct. Mol. Biol.* **14**, 295–300 (2007).
23. De Strooper, B. et al. A presenilin-1-dependent γ -secretase-like protease mediates release of Notch intracellular domain. *Nature* **398**, 518–522 (1999).
24. Brou, C. et al. A novel proteolytic cleavage involved in Notch signaling: the role of the disintegrin-metalloprotease TACE. *Mol. Cell* **5**, 207–216 (2000).
25. Schroeter, E. H., Kisslinger, J. A. & Kopan, R. Notch-1 signalling requires ligand-induced proteolytic release of intracellular domain. *Nature* **393**, 382–386 (1998).
26. Varnum-Finney, B. et al. Immobilization of Notch ligand, Delta-1, is required for induction of notch signaling. *J. Cell Sci.* **113**, 4313–4318 (2000).
27. Trotman-Grant, A. C. et al. DL4- μ beads induce T cell lineage differentiation from stem cells in a stromal cell-free system. *Nat. Commun.* **12**, 5023 (2021).
28. Li, K. et al. Modulation of Notch signaling by antibodies specific for the extracellular negative regulatory region of Notch3. *J. Biol. Chem.* **283**, 8046–8054 (2008).
29. Tiyanont, K., Wales, T. E., Siebel, C. W., Engen, J. R. & Blacklow, S. C. Insights into Notch3 activation and inhibition mediated by antibodies directed against its negative regulatory region. *J. Mol. Biol.* **425**, 3192–3204 (2013).
30. Xu, X. et al. Insights into autoregulation of Notch3 from structural and functional studies of its negative regulatory region. *Structure* **23**, 1227–1235 (2015).
31. Ilagan, M. X. G., Lim, S., Fulbright, M., Piwnicka-Worms, D. & Kopan, R. Real-time imaging of Notch activation with a luciferase complementation-based reporter. *Sci. Signal.* **4**, rs7(2011).
32. Smyrlaki, I. et al. Soluble and multivalent Jag1 DNA origami nanopatterns activate Notch without pulling force. *Nat. Commun.* **15**, 465 (2024).
33. Mout, R. et al. Design of soluble Notch agonists that drive T cell development and boost immunity. *Cell* **188**, 1–15 (2025).
34. Gonzalez-Perez, D. et al. Affinity-matured DLL4 ligands as broad-spectrum modulators of Notch signaling. *Nat. Chem. Biol.* **19**, 9–17 (2023).
35. Sprinzak, D. et al. Cis-interactions between Notch and Delta generate mutually exclusive signalling states. *Nature* **465**, 86–90 (2010).
36. Cordle, J. et al. A conserved face of the Jagged/Serrate DSL domain is involved in Notch *trans*-activation and *cis*-inhibition. *Nat. Struct. Mol. Biol.* **15**, 849–857 (2008).
37. Braun, M. B. et al. Peptides in headlock—a novel high-affinity and versatile peptide-binding nanobody for proteomics and microscopy. *Sci. Rep.* **6**, 19211 (2016).
38. Andersson, E. R. et al. Mouse model of Alagille syndrome and mechanisms of *Jagged1* missense mutations. *Gastroenterology* **154**, 1080–1095 (2018).
39. Lafkas, D. et al. Therapeutic antibodies reveal Notch control of transdifferentiation in the adult lung. *Nature* **528**, 127–131 (2015).
40. Powles, T. et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. *Nature* **515**, 558–562 (2014).
41. Xiao, D. et al. Development of bifunctional anti-PD-L1 antibody MMAE conjugate with cytotoxicity and immunostimulation. *Bioorg. Chem.* **116**, 105366 (2021).
42. Zammarchi, F. et al. ADCT-402, a PBD dimer-containing antibody drug conjugate targeting CD19-expressing malignancies. *Blood* **131**, 1094–1105 (2018).
43. Lewis Phillips, G. D. et al. Targeting HER2-positive breast cancer with trastuzumab–DM1, an antibody–cytotoxic drug conjugate. *Cancer Res.* **68**, 9280–9290 (2008).
44. Yellin, M. J. et al. CD40 molecules induce down-modulation and endocytosis of T cell surface T cell–B cell activating molecule/CD40-L. Potential role in regulating helper effector function. *J. Immunol.* **152**, 598–608 (1994).
45. Hernandez, M. G. H., Shen, L. & Rock, K. L. CD40–CD40 ligand interaction between dendritic cells and CD8⁺ T cells is needed to stimulate maximal T cell responses in the absence of CD4⁺ T cell help. *J. Immunol.* **178**, 2844–2852 (2007).
46. Mitchison, N. A. T-cell–B-cell cooperation. *Nat. Rev. Immunol.* **4**, 308–312 (2004).
47. Naito, M. et al. CD40L-Tri, a novel formulation of recombinant human CD40L that effectively activates B cells. *Cancer Immunol. Immunother.* **62**, 347–357 (2013).
48. Andrawes, M. B. et al. Intrinsic selectivity of Notch 1 for Delta-like 4 over Delta-like 1. *J. Biol. Chem.* **288**, 25477–25489 (2013).
49. Parks, A. L., Klueg, K. M., Stout, J. R. & Muskavitch, M. A. Ligand endocytosis drives receptor dissociation and activation in the Notch pathway. *Development* **127**, 1373–1385 (2000).
50. Koo, B.-K. et al. An obligatory role of Mind bomb-1 in notch signaling of mammalian development. *PLoS ONE* **2**, e1221 (2007).
51. McMillan, B. J. et al. A tail of two sites: a bipartite mechanism for recognition of Notch ligands by Mind bomb E3 ligases. *Mol. Cell* **57**, 912–924 (2015).
52. Cao, R. et al. Structural requirements for activity of Mind bomb1 in Notch signaling. *Structure* **32**, 1667–1676 (2024).
53. Medina, E., Perez, D. H., Antfolk, D. & Luca, V. C. New tricks for an old pathway: emerging Notch-based biotechnologies and therapeutics. *Trends Pharmacol. Sci.* **44**, 934–948 (2023).
54. Bonnici, L., Suleiman, S., Schembri-Wismayer, P. & Cassar, A. Targeting signalling pathways in chronic wound healing. *Int. J. Mol. Sci.* **25**, 50 (2024).
55. Tan, S. et al. Distinct PD-L1 binding characteristics of therapeutic monoclonal antibody durvalumab. *Protein Cell* **9**, 135–139 (2018).
56. Troise, F., Cafaro, V., Giancola, C., D'Alessio, G. & De Lorenzo, C. Differential binding of human immunoagents and Herceptin to the ErbB2 receptor. *FEBS J.* **275**, 4967–4979 (2008).

57. Mazor, Y. et al. Enhanced tumor-targeting selectivity by modulating bispecific antibody binding affinity and format valence. *Sci. Rep.* **7**, 40098 (2017).
58. Haber, L. et al. Generation of T-cell-redirecting bispecific antibodies with differentiated profiles of cytokine release and biodistribution by CD3 affinity tuning. *Sci. Rep.* **11**, 14397 (2021).
59. del Álamo, D., Rouault, H. & Schweisguth, F. Mechanism and significance of *cis*-inhibition in Notch signalling. *Curr. Biol.* **21**, R40–R47 (2011).
60. Boyd, N. et al. 'Off-the-shelf' immunotherapy: manufacture of CD8⁺ T cells derived from hematopoietic stem cells. *Cells* **10**, 2631 (2021).
61. Mensurado, S., Blanco-Domínguez, R. & Silva-Santos, B. The emerging roles of $\gamma\delta$ T cells in cancer immunotherapy. *Nat. Rev. Clin. Oncol.* **20**, 178–191 (2023).
62. Patni, A. P. et al. Designed soluble Notch agonist drives human ameloblast maturation for tooth regeneration. Preprint at *bioRxiv* <https://doi.org/10.1101/2025.04.03.646929> (2025).

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2025

Methods

Protein expression and purification

All SNAG sequences were cloned into a pAcGP67A vector for insect cell production containing an N-terminal gp67 signal peptide and C-terminal 8×His tag. Monomeric SNAGs were generated by fusing a truncated version of the Delta^{MAX} protein spanning from the N terminus to EGF5 (N–EGF5) fused to a biomarker-targeting scFv or nanobody using a flexible (GS)₃ linker. Dimeric SNAG^{Fc} constructs were generated by fusing Delta^{MAX} (N–EGF5) and the biomarker-targeting module to the N and C termini of a human IgG1 Fc domain, respectively. All SNAG^{Fc} constructs contained short GSG linkers between the Fc sequence and Delta^{MAX} or the targeting module. Published sequences of atezolizumab, trastuzumab and loncastumab⁶³ were converted into scFv format before being incorporated into SNAGs and the sequence of the BC2-specific nanobody³⁷ was obtained from the Protein Data Bank (PDB 5VIN). Each scFv was generated by fusing the C terminus of the variable heavy domain to the N terminus of the variable light domain with a (GGGS)₃ linker. Biotinylated Delta^{MAX} (N–EGF5) protein was generated through enzymatic modification of a C-terminal biotin acceptor peptide (BirA tag) as previously described³⁴. The DLL4^{HL} mutant was generated by replacing the C2 and DSL domains of human DLL4 with the BC2 peptide sequence, which was connected to the N terminus of EGF1 by a short GSG linker. The DLL4^{HL} construct was cloned into a pLenti-IRES-Puro vector for mammalian expression.

All SNAG constructs in this study were expressed for by infecting *Trichoplusia ni* insect cell cultures (Expression Systems) at a density of 2×10^6 cells per ml with recombinant Baculovirus. Culture supernatants were isolated after 48 h and proteins were purified by nickel and size-exclusion chromatography. Biotinylated proteins were site-specifically modified using BirA ligase and excess biotin was removed by purifying the proteins on a size-exclusion column. Protein purity was assessed by SDS–PAGE using TGX 12% precast gels (Bio-Rad). All proteins were flash-frozen in liquid nitrogen and stored at -80°C following purification.

Cell culture and generation of cell lines

Mammalian cells were cultured at 37°C with a humidified atmosphere of 5% CO₂, washed with Dulbecco's PBS (DPBS; Corning) and detached with trypsin–EDTA 0.25% (Gibco) for subculturing or cell-based assays. Notch reporter CHO-K1 NI-Gal4 cells were a gift from M. Elowitz (California Institute of Technology)³⁵. Briefly, transfections of HEK293T cells were carried out with packaging vectors VSV-G and d8.9 in the presence of polyethyleneimine at a ratio of 4:1 (DNA to polyethyleneimine). HER2⁺ SK-BR-3 cells, human CD19-overexpressing 3T3 cells, PDL1⁺ MDA-MB-231 and CD40⁺ OCI-Ly3 cells were gifts from B. Czerniecki, F. Locke, E. Lau and J. Cleveland, respectively (Moffit Cancer Center). HEK293T cells, SK-BR-3 cells, 3T3 mouse fibroblasts and MDA-MB-231 cells were cultured in high-glucose DMEM (Cytiva) supplemented with 10% FBS (peak serum) and 2% penicillin–streptomycin (Gibco). Puromycin ($5 \mu\text{g ml}^{-1}$) was added to HEK293T cell cultures to maintain homogeneous populations of receptor-expressing cells. CHO-K1 NI-Gal4 cells were cultured in α -MEM (Cytiva) supplemented with 10% FBS (peak serum), 2% penicillin–streptomycin (Gibco), $400 \mu\text{g ml}^{-1}$ zeocin (Alfa Aesar) and $600 \mu\text{g ml}^{-1}$ geneticin (Gibco). Expression of receptors on the cell surface was confirmed using flow cytometry (BD Accuri C6 plus), by staining the cell lines with anti-hDLL4 PE (Biolegend; 1:100), anti-hJAG1 APC (Biolegend; 1:100), anti-hPDL1 FITC (Biolegend; 1:100) and anti-hHER2 (Cell Signaling Technologies; 1:100) followed by anti-IgG Alexa Fluor 488 (Biolegend; 1:200), anti-hCD19 FITC (Biolegend; 1:100) and anti-hCD40 PE (Biolegend; 1:100) in DMEM supplemented with 10% FBS for 1 h at 4°C .

Notch stimulation with Delta^{MAX} multimers

On day 1, biotinylated Delta^{MAX}, Delta^{MAX} tetramers formed with SA or Delta^{MAX}–Fc was reconstituted in DPBS and adsorbed to tissue culture

96-well plates (Costar) for 1 h at 37°C . The wells were then washed three times with 200 μl of DPBS to remove unbound proteins. Next, CHO-K1 NI-Gal4 cells were detached with trypsin–EDTA 0.25% (Gibco) and manually counted. Appropriate dilutions were prepared in α -MEM to ensure 30,000 CHO-K1 NI-Gal4 cells per well in a volume of 50 μl . Cells were transferred to the ligand-coated plates and cultured for 24 h at 37°C in 5% CO₂. On day 2, CHO-K1 NI-Gal4 cells were washed with 200 μl of DPBS, detached with 30 μl of trypsin–EDTA 0.25% and quenched with 170 μl of α -MEM. Finally, cells were resuspended and the H2B–mCitrine signal was measured by flow cytometry (BD Accuri C6 plus). CHO-K1 NI-Gal4 cells alone were used as the control. The measurements represent the mean fluorescence intensity (MFI) as the fold change of Notch activation \pm s.d. of three technical replicates. Notch activation was normalized to wells containing CHO-K1 NI-Gal4 cells alone.

Notch activation with SNAGs in coculture of cells expressing the target biomarker

On day 1, cells expressing the target receptor of the SNAG (signal-sending cells) were detached with trypsin–EDTA and counted manually; dilutions were prepared such that 50 μl of DMEM containing 15,000 signal-sending cells were added to the wells of a tissue culture 96-well plate. The next day, CHO-K1 NI-Gal4 reporter cells (signal-receiving cells) were detached with trypsin–EDTA and 50 μl of α -MEM containing 30,000 cells was added to the tissue culture 96-well plate containing the signal-sending cells after combining with the indicated Delta^{MAX} or SNAG protein. For the CD40-SNAG experiments, the difference was that an equal number of signal-sending and signal-receiving cells were added same day. Wells without signal-sending cells were used to determine background activation of Notch by Delta^{MAX} and SNAGs. When testing inhibition of endocytosis, 80 μM of dynamin inhibitor 1 (Dynasore, Sigma) was added to the mixture of Notch reporter cells with protein and added to the tissue culture 96-well plate containing the signal-sending cells. Notch activation was measured as previously described.

Comparison of SNAGs to conventional methods of Notch activation

On day 1, cells expressing the canonical Notch ligand, DLL4 and PDL1⁺ MDA-MB-231 cells expressing the target receptor of the SNAG were detached with trypsin–EDTA and counted manually; dilutions were prepared such that 50 μl of DMEM containing 15,000 signal-sending cells was added to wells of a tissue culture 96-well plate. The next day, Delta^{MAX}–Fc and DLL4–Fc in DPBS were adsorbed to tissue culture 96-well plates (Costar) for 1 h at 37°C . The wells were then washed three times with 200 μl of DPBS to remove unbound proteins. Next, CHO-K1 NI-Gal4 cells were detached with trypsin–EDTA 0.25% (Gibco) and manually counted. Appropriate dilutions were prepared in α -MEM to ensure 30,000 CHO-K1 NI-Gal4 cells per well in a volume of 50 μl . Cells were transferred to wells with adsorbed ligands and signal-sending cells only or after combining with Delta^{MAX}–Fc and EDTA (1.0 mM final concentration) or in coculture with PDL1-SNAG^{Fc} with or without DAPT (3 μM final concentration) and cultured for 24 h at 37°C in 5% CO₂. On day 2, CHO-K1 NI-Gal4 cells were washed with 200 μl of DPBS, detached with 30 μl of trypsin–EDTA 0.25% and quenched with 170 μl of α -MEM. Finally, cells were resuspended and the H2B–mCitrine signal was measured by flow cytometry (BD Accuri C6 plus). CHO-K1 NI-Gal4 cells alone were used as the control. The measurements represent the MFI as the fold change of Notch activation \pm s.d. of three technical replicates. Notch activation was normalized to wells containing CHO-K1 NI-Gal4 cells alone.

Western blot detection of Notch1 activation by the PDL1-SNAG^{Fc} in MDA-MB-231 cells

Delta^{MAX} (100 nM protein in 600 μl of DPBS) was nonspecifically adsorbed to a single well of a 12-well plate for 1 h at 37°C as a positive

control for Notch1 activation. The positive control well and three additional wells were then seeded with 200×10^3 MDA-MB-231 cells. The plate was centrifuged at 400g for 4 min to ensure that cells were retained at the bottom of each well; then, the media of all wells were discarded. In the first uncoated well, 600 μ l of DMEM was added as a negative control. The second well was filled with 600 μ l of medium containing 100 nM of Delta^{MAX}-Fc to monitor Notch1 activation by soluble ligand. The third was filled with 600 μ l of medium containing 100 nM PDL1-SNAG^{Fc}. The following day, the media were aspirated from all four wells and the samples were resuspended in 60 μ l of Laemmli sample buffer with 5% β -mercaptoethanol to lyse cells, followed by boiling at 100 °C for 4 min. Lastly, the samples were analyzed by western blotting using equal protein amounts of cell lysates separated by SDS-PAGE (12% Mini-PROTEAN TGX precast protein gels, Bio-Rad) and transferred to PVDF membranes using an iBlot2 gel transfer device (Thermo Fisher Scientific). The membranes were blocked in 3% BSA + 0.1% TBS-Tween. Primary antibodies were anti-Notch1 (D1E11 rabbit monoclonal antibody, Cell Signaling Technology; 1:1,000), anti-cleaved Notch1 (Val1744 rabbit monoclonal antibody, Cell Signaling Technology; 1:1,000) and anti- β -actin (rabbit polyclonal antibody, Cell Signaling Technology; 1:1,000). Secondary antibody anti-rabbit IgG conjugated to horseradish peroxidase (goat polyclonal antibody, Vector Laboratories; 1:8,000) was used for the detection of proteins using SuperSignal West Pico PLUS chemiluminescent substrate (Thermo Fisher Scientific). Images were acquired using a Chemidoc Imaging System and analyzed with Image-Lab version 6 software (Bio-Rad).

Immunofluorescence cell staining

For endocytosis assays, cells were grown on glass-like polymer bottoms in 24-well black-frame plates (Cellvis). For visualization of CD19-SNAG^{Fc} protein binding, 500 nM protein was preincubated with anti-Fc 647 (Alexa Fluor) at 1:200 dilution for 1 h on rotation at 4 °C. The CD19-SNAG^{Fc}-647 solution was added to cells on ice that were further kept at 4 °C for 1 h. For endocytosis, the incubation was followed by washing away nonbound CD19-SNAG^{Fc}-647 with PBS and 37 °C DMEM was added to the cells followed by a 15-min incubation in a 37 °C incubator. After incubation of CD19-SNAG^{Fc}-647 with or without endocytosis, the cells were fixed in 3% paraformaldehyde and permeabilized with 0.15% Triton X-100 in PBS for 10 min at room temperature. Nonspecific binding was blocked by incubation in 3% BSA in PBS with 0.05% Triton X-100 and 0.1 M glycine for 60 min at room temperature. Cells were further stained for filamentous actin with Alexa 488 conjugated to phalloidin (Invitrogen) for 45 min to visualize contours of the individual cells. Hoechst 33342 (Invitrogen) was used to counterstain nuclei. Images were acquired using a Keyence BZ-X710 microscope using a Nikon Plan Apo $\times 20$ objective. The far-red channel (magenta) was processed with the dehaze function in the BZ-X710LE analyzer software. A minimum of 100 cells were imaged for each condition.

Treatment of CD8⁺ T cells with HER2-SNAG^{Fc} and PDL1-SNAG^{Fc}

Human CD8⁺ T cells were purified from peripheral blood mononuclear cells (PBMCs) using the MagniSort human CD8⁺ T cell enrichment kit (Invitrogen, 8804-6812-74) according to the manufacturer's protocol. Naive CD8⁺ T cells were then cocultured at a 1:1 ratio with PDL1⁺ MDA-MB-231 cells or HER2⁺ SK-BR-3 cells, with or without Delta^{MAX}-Fc or SNAG^{Fc}. To enhance cell-cell contact, cultures were subjected to a short centrifugation at 300g for 1 min. T cells were activated by adding human CD3 and CD28 Dynabeads (Gibco, 11161D). After 48 h of stimulation, cells were treated with BD GolgiStop protein transport inhibitor (BD Biosciences, 554724) for 4 h. Fixation and permeabilization were performed using the BD Cytotfix/Cytoperm fixation and permeabilization kit (BD Biosciences, 554714) according to the manufacturer's protocol. Cells were then stained with human anti-IFN γ (APC), anti-GrB

(FITC) and anti-CD8 (PE) antibodies and DAPI followed by flow cytometry analysis. Data were quantified by FlowJo 10 software. To quantify relative mRNA levels, the total RNA was extracted using TRIzol reagent (Invitrogen, 15596026). Complementary DNA (cDNA) synthesis was performed using 500 ng of purified RNA with the Verso cDNA synthesis kit (Thermo Fisher Scientific, AB1453B). qPCR was conducted using primers specific for IFN γ , GrB, HES4 and B2M. Gene expression levels were normalized to B2M as an internal control and fold changes were calculated relative to the control condition.

Reporting summary

Further information on research design is available in the Nature Portfolio Reporting Summary linked to this article.

Data availability

All data generated in this study are available within the article; additional raw data are available from the corresponding author upon request. Source data are provided with this paper.

References

63. Abanades, B. et al. The Patent and Literature Antibody Database (PLAbDab): an evolving reference set of functionally diverse, literature-annotated antibody sequences and structures. *Nucleic Acids Res.* **52**, D545–D551 (2024).

Acknowledgements

This project was supported by the National Institutes of Health (NIH) R35GM133482 (V.C.L.), R01CA233512 (P.C.R.), R01CA262121 (P.C.R.), R01CA273034 (P.C.R.), P01CA250984 project number 4 (P.C.R) and the Sigrid Juselius Foundation (D.A.). V.C.L. is a Rita Allen Scholar. Shared resources were provided by the Moffitt Cancer Center Support Grant (NIH P30CA076292).

Author contributions

V.C.L. and D.H.P. wrote the paper. V.C.L., D.H.P. D.A., P.C.R. and S.C. designed the experiments. D.H.P. cloned the SNAG constructs, purified the proteins and performed the signaling assays. E.M. and D.G.P. generated the Delta^{MAX} constructs. D.A. performed the western blot analysis and immunofluorescence endocytosis assays. S.C. performed the T cell coculture assays. X.E.B. and D.A.D. assisted with the T cell assays. A.A.R. generated the CD40-SNAG construct. V.C.L. supervised the project and edited the paper.

Competing interests

V.C.L. is a consultant on unrelated projects for CellaBio Biotech, Remunix and CurieBio. V.C.L. and D.H.P. have filed provisional patents (63/548,615 and 63/663,744) based on the described technology. The other authors declare no competing interests.

Additional information

Supplementary information The online version contains supplementary material available at <https://doi.org/10.1038/s41589-025-02030-y>.

Correspondence and requests for materials should be addressed to Vincent C. Luca.

Peer review information *Nature Chemical Biology* thanks the anonymous reviewer(s) for their contribution to the peer review of this work.

Reprints and permissions information is available at www.nature.com/reprints.

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our [Editorial Policies](#) and the [Editorial Policy Checklist](#).

Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

n/a Confirmed

- The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
- A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
- The statistical test(s) used AND whether they are one- or two-sided
Only common tests should be described solely by name; describe more complex techniques in the Methods section.
- A description of all covariates tested
- A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
- A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
- For null hypothesis testing, the test statistic (e.g. F , t , r) with confidence intervals, effect sizes, degrees of freedom and P value noted
Give P values as exact values whenever suitable.
- For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
- For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
- Estimates of effect sizes (e.g. Cohen's d , Pearson's r), indicating how they were calculated

Our web collection on [statistics for biologists](#) contains articles on many of the points above.

Software and code

Policy information about [availability of computer code](#)

Data collection

All software used in this study for data collection and analysis was commercial. For flow cytometry experiments BD Accuri C6 plus instrument was used with BD CSampler plus software v1.0.23.1. Protein purification was carried out in an Akta Pure using Unicorn v7.1. Cell sorting to generate cell lines was done with a Sony SH800 and cell sorter software v2.1.5. Images for Western Blot regarding Notch activation were acquired using a Chemidoc Imaging System and analyzed in Biorad Image-lab v6. Cell staining experiments were imaged using a Keyence BZ-X710 microscope using a Nikon Plan Apo objective and analyzed using BZ-X710LE analyzer software.

Data analysis

Data analysis was done using GraphPad Prism v9 software and corresponding p-values are shown in the corresponding figure. Notch activation was normalized to the mean MFI of the Notch reporter cells of each respective biological replicate. In T cell experiments the values were normalized to the control (untreated) group of each respective biological replicate.

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio [guidelines for submitting code & software](#) for further information.

Data

Policy information about [availability of data](#)

All manuscripts must include a [data availability statement](#). This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our [policy](#)

The authors declare that all the data generated in this study are available within the article, the raw data used for graphs and figures are available as Source data, and any additional raw data are available from the corresponding author upon request.

Human research participants

Policy information about [studies involving human research participants and Sex and Gender in Research](#).

Reporting on sex and gender	N/A
Population characteristics	N/A
Recruitment	N/A
Ethics oversight	N/A

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

- Life sciences Behavioural & social sciences Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see [nature.com/documents/nr-reporting-summary-flat.pdf](https://www.nature.com/documents/nr-reporting-summary-flat.pdf)

Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size	No sample size calculation was needed for this study. Three biological replicates were selected since they are enough to determine differences between the proteins tested. Each biological replicate contained at minimum three technical replicates to account for variation due to experimental setup.
Data exclusions	No data was excluded
Replication	All attempts at replication were successful and demonstrated by the use of both a minimum of triplicate technical and biological replicates. Variation within the T cell experiments were expected due to biological variation in the donor samples used.
Randomization	Covariates do not change in this study; therefore, randomization is not relevant for this study.
Blinding	Blinding was not relevant to the study, but there was not specific order of measurement that could introduce a bias.

Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

Materials & experimental systems

Methods

n/a	Involved in the study
<input type="checkbox"/>	<input checked="" type="checkbox"/> Antibodies
<input type="checkbox"/>	<input checked="" type="checkbox"/> Eukaryotic cell lines
<input checked="" type="checkbox"/>	<input type="checkbox"/> Palaeontology and archaeology
<input checked="" type="checkbox"/>	<input type="checkbox"/> Animals and other organisms
<input checked="" type="checkbox"/>	<input type="checkbox"/> Clinical data
<input checked="" type="checkbox"/>	<input type="checkbox"/> Dual use research of concern

n/a	Involved in the study
<input checked="" type="checkbox"/>	<input type="checkbox"/> ChIP-seq
<input type="checkbox"/>	<input checked="" type="checkbox"/> Flow cytometry
<input checked="" type="checkbox"/>	<input type="checkbox"/> MRI-based neuroimaging

Antibodies

Antibodies used

anti-hDLL4 PE mAb clone MHD4-46, Biolegend, Cat#346506, RRID:AB_2092809
 anti-hJAG1 APC mAb clone W161998, Biolegend Cat#399103, RRID:AB_2890847
 anti-hPDL1 FITC mAb clone MIH3, Biolegend Cat#374509, RRID:AB_2734437
 anti-hHER2 mAb clone 29D8, Cell Signaling Technology Cat#2165, RRID:AB_10692490
 anti-hCD19 FITC mAb clone SJ25C1, Biolegend Cat#363007, RRID:AB_2564170
 anti-hCD40 PE mAb clone 5C3, Biolegend Cat#334307, RRID:AB_1186060
 anti-hNotch1 mAb clone D1E11, Cell Signaling Technology Cat#3608, RRID:AB_2153354
 anti-cleaved Notch1 mAb clone D3B8, Cell Signaling Technology Cat#4147, RRID:AB_2153348
 anti-beta actin Rabbit polyclonal Ab, Cell Signaling Technology Cat#4967, RRID:AB_330288
 anti-hCD8 (PE), BioLegend Cat# 300908, RRID:AB_314112
 anti-hIFN γ (APC), BioLegend Cat# 502512, RRID:AB_315237
 anti-hgranzyme B FITC, BioLegend Cat# 396404, RRID:AB_2801073
 anti-IgG Rabbit polyclonal Ab HRP conjugated, Vector Laboratories Cat#PI-1000-1, RRID:AB_2916034
 anti-Human IgG Fc-AF647, Southern Biotech Cat# 2048-31, RRID:AB_2795692
 anti-human IgG Fc-AF488 BioLegend Cat# 410705, RRID:AB_2565783

Validation

Manufacturer validated each respective antibody using endogenously or transfected cell lines. Specific validations done in the study are contained within the manuscript.

Eukaryotic cell lines

Policy information about [cell lines and Sex and Gender in Research](#)

Cell line source(s)

HEK293T and MDA-MB-231 cells were a gift from Dr. Eric Lau (Moffitt Cancer Center, FL original commercial source ATCC). CHO-K1 Notch1-Gal4 cells were a gift from Dr. David Sprinzak (Tel Aviv University, Israel, original commercial source Invitrogen). SK-BR-3 cells were a gift from Dr. Brian Czerniecki (Moffitt Cancer Center, FL original commercial source ATCC). CD19-overexpressing 3T3 cells were a gift from Dr. Fred Locke (Moffitt Cancer Center, FL original commercial source ATCC). OCI-Ly3 cells were a gift from Dr. John Cleveland (Moffitt Cancer Center, FL original commercial source ATCC). HiFive insect cells were from Expression systems.

Authentication

All cell lines were confirmed to have surface expression of the corresponding receptor using antibodies targeting each receptor and quantified using flow cytometry.

Mycoplasma contamination

All cells lines were tested for Mycoplasma prior to use using the established kit by ATCC.

Commonly misidentified lines
(See [ICLAC](#) register)

No commonly misidentified cell lines were used in this study.

Flow Cytometry

Plots

Confirm that:

- The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).
- The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).
- All plots are contour plots with outliers or pseudocolor plots.
- A numerical value for number of cells or percentage (with statistics) is provided.

Methodology

Sample preparation

Mammalian cells were washed with DPBS and detached with trypsin-EDTA followed by centrifugation to remove residual trypsin-EDTA and staining with the corresponding antibody was done in DMEM supplemented with 10% FBS for 1 h at 4 degrees celsius. Notch activation assays were performed using the same method of cell preparation except that reporter cells

were resuspended in Alpha-MEM supplemented with 10% FBS prior to quantification at room temperature. Further details are included in the methods section of the manuscript.

Instrument

BD Accuri C6 plus

Software

Data collection was performed using BD CSampler Plus Software v1.0.23.1 and analysis was done using FlowJo v10.7.2.

Cell population abundance

Reporter cells were gated to confirm population abundance over the total number of cells in co-culture assays to ensure a 1:1 ratio of cells.

Gating strategy

To isolate reporter cells the (log-log) PE-A vs FITC-A was used to take advantage of the background FITC signal of the reporter cells followed by doublet discrimination using (linear-linear) FSC-H vs FSC-A, and the diagonal line for a ratio of 1:1 was gated for singlets. Lastly, the gated single cells were plotted using (log-log) SSC-A vs FITC-A. In the case of cell stainings for receptor expression the initial gate was (log-log) SSC-A vs FSC-A and the single cells were plotted using (log-log) SSC-A vs FITC-A, PE-A, or APC-A depending on the fluorophore used.

Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.